Upcoming Webinars
Data Privacy and Digital Health: The Manufacturers/Payers Perspective
Wednesday, July 27, 2022
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Differentiating between Patient Preferences, Patient Reported Outcomes and Patient Engagement
Wednesday, September 7, 2022
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Thursday, September 8, 2022
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Network Meta-Analysis - Special Topics: A Webinar by the ISPOR Statistical Methods in HEOR Special Interest Group
Thursday, September 22, 2022
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Friday, September 30, 2022
09:00AM EDT | 1:00PM UTC | 3:00PM CEST
Most Recent
Jun 2022
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Sponsored by AstraZeneca
Jun 2022
For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.
Sponsored by Charles River Associates
Jun 2022
This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society.
May 2022
Sponsored by MDClone
May 2022
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Sponsored by Merck & Co., known as MSD outside the United States and Canada
May 2022
Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.
Clinical Outcomes
Sponsored by AstraZeneca
Jun 2022
For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.
Sponsored by MDClone
May 2022
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Apr 2022
Speakers will discuss the many uses of COA data gathered during patient-focused drug development, including benefit/risk evaluation, HTA, access decisions, policy decisions, and clinician and patient decision-making.
Apr 2022
The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.
Economic Evaluation
Jun 2022
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Sponsored by AstraZeneca
Jun 2022
For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.
Sponsored by Merck & Co., known as MSD outside the United States and Canada
May 2022
Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.
Apr 2022
Health systems in Asia Pacific regions are under tremendous pressure to deal with the rising costs, unequal access to service, and uneven quality of care. More and more healthcare systems across the region have increasingly embraced a value-based health care (VBHC) agenda. How can we maximize value for money and optimize patient outcomes? How should healthcare be delivered and reimbursed? In light of these issues, this webinar brings together a panel of experts to discuss the current situation of value-based payment in the Asia Pacific region and beyond, challenges and opportunities for VBHC implementation in the region.
Health Technology Assessment
Jun 2022
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Sponsored by AstraZeneca
Jun 2022
For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.
Sponsored by Merck & Co., known as MSD outside the United States and Canada
May 2022
Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.
Apr 2022
Health systems in Asia Pacific regions are under tremendous pressure to deal with the rising costs, unequal access to service, and uneven quality of care. More and more healthcare systems across the region have increasingly embraced a value-based health care (VBHC) agenda. How can we maximize value for money and optimize patient outcomes? How should healthcare be delivered and reimbursed? In light of these issues, this webinar brings together a panel of experts to discuss the current situation of value-based payment in the Asia Pacific region and beyond, challenges and opportunities for VBHC implementation in the region.
Real-World Data & Information Systems
Sponsored by MDClone
May 2022
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Sponsored by Biogen
Apr 2022
This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.
Apr 2022
The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.
Sponsored by Medtronic
Mar 2022
Experts from around the world will be sharing their experience about obesity treatment and reimbursement policies in their different countries. The event will consist of 7 expert presentations followed by a round table discussion with an opportunity for the audience to ask questions.
Patient-Centered Research
Sponsored by AstraZeneca
Jun 2022
For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.
Sponsored by MDClone
May 2022
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Apr 2022
The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.
Jan 2022
This webinar will be useful for researchers, regulators, academics, industry sponsors, and instrument developers in the clinical outcomes assessment (COA) field working on the development, evaluation, and implementation of performance outcome (PerfO) measures for use in capturing clinical benefits in treatment trials for medical label claims.
Methodical & Statistical Research
Jun 2022
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Sponsored by MDClone
May 2022
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Sponsored by Biogen
Apr 2022
This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.
Feb 2021
Many preference researchers have been quick to respond to this need and have conducted empirical COVID19 studies to better understand the value of health and health-related policies.
Health Policy & Regulatory
Jun 2022
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Sponsored by AstraZeneca
Jun 2022
For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.
Sponsored by Charles River Associates
Jun 2022
This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society.
Sponsored by Merck & Co., known as MSD outside the United States and Canada
May 2022
Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.
Study Approaches
Oct 2020
In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.
Jun 2020
This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.
Apr 2020
This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.
Sponsored by MDClone
May 2022
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Nov 2020
This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.
Nov 2020
COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of the public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame?
Oct 2020
This webinar features a range of international speakers who will introduce several One Health-related topics as they pertain to HEOR, with a view gauging interest in the formation of an ISPOR Animal and One Health Special Interest Group (SIG).
Sep 2021
During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.
Feb 2021
This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.
Oct 2020
The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.
Sponsored by Biogen
Feb 2021
This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.
Dec 2020
This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.
Nov 2020
This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.
Oct 2020
This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.
Need More Information or Have Questions?
Contact us for more information on ISPOR education and training.